SenesTech Inc (NASDAQ:SNES) gapped up before the market opened on Wednesday . The stock had previously closed at $2.32, but opened at $2.11. SenesTech shares last traded at $2.11, with a volume of 2097859 shares trading hands.
A number of equities research analysts recently issued reports on the stock. Zacks Investment Research raised shares of SenesTech from a “sell” rating to a “hold” rating in a research note on Wednesday. ValuEngine raised shares of SenesTech from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. Finally, Roth Capital reaffirmed a “buy” rating on shares of SenesTech in a research note on Wednesday, April 4th.
The company has a market cap of $34.90 million, a PE ratio of -1.75 and a beta of 3.78. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.89 and a current ratio of 5.65.
SenesTech (NASDAQ:SNES) last released its quarterly earnings results on Monday, May 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.01). The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.25 million. SenesTech had a negative net margin of 17,962.50% and a negative return on equity of 205.29%. analysts predict that SenesTech Inc will post -0.5 earnings per share for the current fiscal year.
A hedge fund recently bought a new stake in SenesTech stock. CVI Holdings LLC acquired a new stake in shares of SenesTech Inc (NASDAQ:SNES) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 513,682 shares of the company’s stock, valued at approximately $262,000. SenesTech comprises 0.4% of CVI Holdings LLC’s portfolio, making the stock its 26th largest holding. CVI Holdings LLC owned approximately 3.11% of SenesTech as of its most recent filing with the Securities and Exchange Commission (SEC). 22.09% of the stock is owned by institutional investors and hedge funds.
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including plant-based fertility control, feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.